KPV is not approved by the U.S. FDA for human use and is not lawful to administer to humans. Where it is offered for sale in the U.S., it is sold only as a 'Research Use Only' laboratory chemical, not as a medicine.
Status as of July 14, 2026
KPV is a synthetic lysine-proline-valine tripeptide, the C-terminal fragment of the larger alpha-MSH hormone, and the way it is supplied and delivered tracks the effect being pursued rather than any approved product standard, because it has none. The published record describes three physical forms, and the route a person reaches for follows the target compartment: systemic, skin, or intestine.
KPV is a synthetic lysine-proline-valine tripeptide from the C-terminal of alpha-MSH, supplied mainly as a lyophilized powder for subcutaneous injection alongside less common topical and oral forms, none of which is an FDA-approved human product.
The three forms KPV is encountered in are not equally common, and each one is tied to a delivery strategy rather than offered interchangeably. The record reports the same caveat cutting across all three: with no approved product standard, the true peptide content of any powder vial, cream, or capsule is not guaranteed by its label.
KPV is supplied in three forms, a lyophilized powder for injection, a topical cream or gel, and an uncommon oral capsule, and because no approved standard governs any of them, true peptide content and purity vary by supplier.
Reconstitution turns the dry cake into an injectable solution, and the published protocols dwell on the details precisely because no pharmacist standardizes the step. The real failure modes described are a non-preserved solvent stored for days, contamination from mishandling, and degradation of the peptide through rough mixing or heat.
Published reconstitution protocols describe adding 2 milliliters of bacteriostatic water to a 10 milligram vial to reach 5 milligrams per milliliter, measured with a unit-graduated insulin syringe, though no pharmacist standardizes the step and it is not validated human therapy.
Route selection comes down to where the peptide is meant to act, and the three routes map onto three different targets that are not interchangeable. A convenient route aimed at the wrong compartment simply will not put the peptide where the reported goal lies, which is why bioavailability and target must be read together.
| Route | Target compartment | Systemic bioavailability |
|---|---|---|
| Subcutaneous injection | Body-wide, via the fat layer | Highest, most predictable of the three |
| Topical cream or gel | Local dermatological site | Low and variable past the skin |
| Oral or targeted-intestinal | Intestinal wall, via PepT1 | Minimal systemic, potential local uptake |
Subcutaneous injection delivers the highest fraction of intact KPV to the bloodstream, topical delivery reaches only a small and variable amount past the skin, and the oral route targets the intestinal wall through PepT1 rather than systemic circulation, with none an established approved therapy.
Oral delivery fights the entire design of the digestive system, which exists to break proteins and peptides down into their building blocks. What makes KPV interesting despite this is its size: a tripeptide sits in exactly the class the gut's PepT1 transporter is built to carry, which reframes the oral route as one aimed at the intestine itself rather than the whole body.
KPV is a tripeptide of the size class the intestinal PepT1 transporter actively carries, which is why the oral route is understood as targeting local intestinal uptake rather than systemic absorption, and why unprotected oral peptide is otherwise largely degraded in the digestive tract.
The skin is engineered to keep things out, and that is exactly the obstacle a topical peptide meets. How much KPV actually reaches the living layers depends heavily on the state of the skin at the application site, which is why the same cream behaves very differently on intact versus compromised skin.
The stratum corneum blocks most of a topically applied peptide because KPV is relatively large and carries charged groups, so only a small and variable fraction crosses intact skin, and topical use remains an unvalidated route rather than an approved medicine.
Regulatory approval is what normally guarantees a labeled dose is the real dose, and KPV has none, which changes everything about trusting a product. A research-chemical peptide sits entirely outside the pharmacopeial system, so no authority defines or checks what a KPV vial must contain, and the label becomes a claim rather than a guarantee.
Because KPV carries no enforced pharmacopeial standard, its labeled content is a claim rather than a guarantee, purity and concentration vary by supplier, and only independent HPLC paired with mass spectrometry can confirm what a given vial actually holds.
Dosing is the sharpest edge of KPV's unapproved status, because a dose only means something when the product and the target effect are both standardized, and here neither is. No regulator has ever approved a human indication, so there is no official dose and no dose-response data from controlled human trials to anchor a number.
KPV has no approved human indication, no dosing schedule, and no controlled human dose-response data, so any circulating number, whether scaled from animal studies or drawn from self-experimentation, is an unvalidated assumption rather than a therapeutic dose.
Peptide stability depends on the form, and the general rule the record reports is that dry is durable while dissolved is fragile. Across every form the same environmental enemies apply, so heat, light, air, and repeated freeze-thaw cycles all shorten how long the tripeptide stays intact.
Sealed lyophilized KPV powder is the most stable form and is kept cold and dry, while a reconstituted solution stays usable only on the order of weeks with a bacteriostatic diluent, and with no approved standard behind it this storage guidance reflects general peptide chemistry rather than a validated shelf-life claim.
Educational use only. This article describes what the published scientific and clinical literature reports about KPV. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
